Additionally, the potential of pairing DCA with rociletinib, a third-generation EGFR-TKI, in combination with radiation therapy has been demonstrated as a promising therapeutic strategy in NSCLC cell line models in vitro20. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.